Login to Your Account



Pending Merger, Archemix Inks Potential $1.4B Deal with GSK

By Catherine Hollingsworth


Wednesday, December 24, 2008
Archemix Corp. and London-based GlaxoSmithKline plc agreed to discover, develop and commercialize aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, in a collaboration that gives Archemix $27.5 million up front. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription